Three distinct businesses that enable us to create high-quality medicines and make them accessible to those who need them.
Diversified business for sustainable growth
Injectables
Branded
Hikma Rx
Manufacturing with quality and reliability
Our manufacturing network spans 29 facilities worldwide, supported by global quality standards and technical expertise. By continually investing in our capabilities and capacity, we help ensure a reliable supply of medicines for patients and healthcare systems around the world.
R&D innovation driven by patient needs
Innovation is key to our growth strategy. Our global R&D organisation develops complex generics, specialty medicines and differentiated products designed to address unmet healthcare needs and improve patient access to treatment.
Where we operate
North America
Our large manufacturing facilities in the United States (US) supply generic and specialty products to the US and Canadian markets across a broad range of therapeutic areas, including respiratory, oncology and pain management. We have an R&D hub in Columbus, Ohio.
MENA
We sell branded generics and in-licensed patented products across the Middle East and North Africa (MENA). We have manufacturing facilities in six MENA countries, including US FDA-inspected plants in Jordan and Saudi Arabia. Around 2,000 sales representatives and support staff market our brands to healthcare professionals across 17 markets. We also have an R&D hub in Amman, Jordan.
Europe
Our injectable manufacturing facilities in Portugal, Italy and Germany have a range of capabilities, including dedicated capacity for oncology and cephalosporins. These facilities supply injectable products to North America, MENA and a growing number of markets in Europe. We also have an R&D hub in Zagreb, Croatia.
Impact in 2025
Delivering better health, every day
We continued to expand access to medicines, invest in innovation and strengthen our global capabilities, helping us serve patients and healthcare providers around the world.
84
new product launches
to address evolving patient and healthcare system needs
4.5%
of revenue invested in R&D
to support future growth and product development
99
regulatory approvals
secured across our global business
825+
medicines in our portfolio
spanning generic, specialty and branded products
9,400+
employees globally
driving innovation and access to medicines